Trials / Completed
CompletedNCT03134573
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 96 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness tracker in the myBETAapp will be observed for 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1b (Betaferon, BAY86-5046) | Solution for injection |
| DEVICE | Betaconnect auto-injector | Auto-injector for application of Betaferon solution which automatically covers injection related data |
| DEVICE | myBETAapp | Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker |
Timeline
- Start date
- 2017-09-15
- Primary completion
- 2018-05-09
- Completion
- 2018-05-09
- First posted
- 2017-05-01
- Last updated
- 2019-03-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03134573. Inclusion in this directory is not an endorsement.